{"id":55176,"date":"2026-01-22T21:12:49","date_gmt":"2026-01-22T13:12:49","guid":{"rendered":"https:\/\/flcube.com\/?p=55176"},"modified":"2026-01-22T21:12:50","modified_gmt":"2026-01-22T13:12:50","slug":"amcellgene-licenses-mesenchymal-stem-cell-therapy-for-aclf-to-advanced-regeneration-in-first-chinese-stem-cell-outbound-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55176","title":{"rendered":"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal"},"content":{"rendered":"\n<p><strong>Tianjin AmCellGene Co., Ltd.<\/strong> has granted <strong>Hong Kong\u2011based Advanced Regeneration<\/strong> exclusive regional rights to commercialize its core pipeline product <strong>Mesenchymal Stem Cells (Umbilical Cord) for Injection<\/strong> for the treatment of <strong>Acute\u2011on\u2011Chronic Liver Failure (ACLF)<\/strong> across the Asia\u2011Pacific region. The agreement, structured as an <strong>upfront payment plus milestones and sales royalties<\/strong>, represents the first successful outbound business development licensing transaction for a domestic Chinese stem cell drug developer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Tianjin AmCellGene<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Advanced Regeneration (Hong Kong)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Exclusive Asia\u2011Pacific regional rights<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Mesenchymal Stem Cells (Umbilical Cord) for Injection<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Acute\u2011on\u2011Chronic Liver Failure (ACLF)<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + milestone payments + sales royalties (specifics undisclosed)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First outbound BD licensing deal for a Chinese stem cell drug company<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-unmet-medical-need\">Drug Profile &amp; Unmet Medical Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Allogeneic umbilical cord\u2011derived mesenchymal stem cells with immunomodulatory and regenerative properties targeting liver failure.<\/li>\n\n\n\n<li><strong>Clinical Progress:<\/strong> Among the fastest\u2011advancing stem cell therapies in China\u2019s regulatory pipeline.<\/li>\n\n\n\n<li><strong>ACLF Mortality:<\/strong> Under traditional care, 28\u2011day mortality rates range from <strong>38% to 52%<\/strong>, with limited effective interventions.<\/li>\n\n\n\n<li><strong>Transplant Shortage:<\/strong> Liver transplantation\u2014the only curative option\u2014is severely constrained by donor availability, creating a critical unmet need for alternative therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-commercial-outlook\">Market Opportunity &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regional Incidence:<\/strong> ACLF affects an estimated <strong>1.5\u20132.0\u202fmillion patients annually<\/strong> in the Asia\u2011Pacific region, driven by high prevalence of hepatitis B and alcohol\u2011related cirrhosis.<\/li>\n\n\n\n<li><strong>Market Potential:<\/strong> Peak sales potential for the therapy is projected at <strong>US$400\u2013600\u202fmillion<\/strong> by 2030 if approved across key markets.<\/li>\n\n\n\n<li><strong>Validation for AmCellGene:<\/strong> The deal validates AmCellGene\u2019s stem cell platform and provides non\u2011dilutive capital to advance its broader pipeline.<\/li>\n\n\n\n<li><strong>Portfolio Boost for Advanced Regeneration:<\/strong> Expands the licensee\u2019s regenerative medicine franchise and establishes its leadership in cell\u2011based liver disease therapies.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, market projections, and financial expectations for the Mesenchymal Stem Cell ACLF therapy. Actual results may differ due to regulatory risks, competition, and market adoption uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tianjin AmCellGene Co., Ltd. has granted Hong Kong\u2011based Advanced Regeneration exclusive regional rights to commercialize&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4570,4569],"class_list":["post-55176","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-advanced-regeneration","tag-amcellgene"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tianjin AmCellGene Co., Ltd. has granted Hong Kong\u2011based Advanced Regeneration exclusive regional rights to commercialize its core pipeline product Mesenchymal Stem Cells (Umbilical Cord) for Injection for the treatment of Acute\u2011on\u2011Chronic Liver Failure (ACLF) across the Asia\u2011Pacific region. The agreement, structured as an upfront payment plus milestones and sales royalties, represents the first successful outbound business development licensing transaction for a domestic Chinese stem cell drug developer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55176\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal\" \/>\n<meta property=\"og:description\" content=\"Tianjin AmCellGene Co., Ltd. has granted Hong Kong\u2011based Advanced Regeneration exclusive regional rights to commercialize its core pipeline product Mesenchymal Stem Cells (Umbilical Cord) for Injection for the treatment of Acute\u2011on\u2011Chronic Liver Failure (ACLF) across the Asia\u2011Pacific region. The agreement, structured as an upfront payment plus milestones and sales royalties, represents the first successful outbound business development licensing transaction for a domestic Chinese stem cell drug developer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55176\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T13:12:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T13:12:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55176#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55176\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal\",\"datePublished\":\"2026-01-22T13:12:49+00:00\",\"dateModified\":\"2026-01-22T13:12:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55176\"},\"wordCount\":355,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Advanced Regeneration\",\"AmCellGene\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55176#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55176\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55176\",\"name\":\"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T13:12:49+00:00\",\"dateModified\":\"2026-01-22T13:12:50+00:00\",\"description\":\"Tianjin AmCellGene Co., Ltd. has granted Hong Kong\u2011based Advanced Regeneration exclusive regional rights to commercialize its core pipeline product Mesenchymal Stem Cells (Umbilical Cord) for Injection for the treatment of Acute\u2011on\u2011Chronic Liver Failure (ACLF) across the Asia\u2011Pacific region. The agreement, structured as an upfront payment plus milestones and sales royalties, represents the first successful outbound business development licensing transaction for a domestic Chinese stem cell drug developer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55176#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55176\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55176#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Tianjin AmCellGene Co., Ltd. has granted Hong Kong\u2011based Advanced Regeneration exclusive regional rights to commercialize its core pipeline product Mesenchymal Stem Cells (Umbilical Cord) for Injection for the treatment of Acute\u2011on\u2011Chronic Liver Failure (ACLF) across the Asia\u2011Pacific region. The agreement, structured as an upfront payment plus milestones and sales royalties, represents the first successful outbound business development licensing transaction for a domestic Chinese stem cell drug developer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55176","og_locale":"en_US","og_type":"article","og_title":"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal","og_description":"Tianjin AmCellGene Co., Ltd. has granted Hong Kong\u2011based Advanced Regeneration exclusive regional rights to commercialize its core pipeline product Mesenchymal Stem Cells (Umbilical Cord) for Injection for the treatment of Acute\u2011on\u2011Chronic Liver Failure (ACLF) across the Asia\u2011Pacific region. The agreement, structured as an upfront payment plus milestones and sales royalties, represents the first successful outbound business development licensing transaction for a domestic Chinese stem cell drug developer.","og_url":"https:\/\/flcube.com\/?p=55176","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T13:12:49+00:00","article_modified_time":"2026-01-22T13:12:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55176#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55176"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal","datePublished":"2026-01-22T13:12:49+00:00","dateModified":"2026-01-22T13:12:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55176"},"wordCount":355,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Advanced Regeneration","AmCellGene"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55176#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55176","url":"https:\/\/flcube.com\/?p=55176","name":"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T13:12:49+00:00","dateModified":"2026-01-22T13:12:50+00:00","description":"Tianjin AmCellGene Co., Ltd. has granted Hong Kong\u2011based Advanced Regeneration exclusive regional rights to commercialize its core pipeline product Mesenchymal Stem Cells (Umbilical Cord) for Injection for the treatment of Acute\u2011on\u2011Chronic Liver Failure (ACLF) across the Asia\u2011Pacific region. The agreement, structured as an upfront payment plus milestones and sales royalties, represents the first successful outbound business development licensing transaction for a domestic Chinese stem cell drug developer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55176#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55176"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55176#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55176"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55176\/revisions"}],"predecessor-version":[{"id":55180,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55176\/revisions\/55180"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}